3 Stocks to Watch as the SpaceX IPO Approaches (GILT, SATL, SATS)

SpaceX has filed its S-1 with the SEC, planning to list on Nasdaq under ticker SPCX with pricing expected June 11 and trading as early as June 12, 2026. The offering could raise up to $75 billion at an implied $1.75 trillion valuation, which would make it the largest IPO in Wall Street history. The filing is a major liquidity and valuation milestone for one of the world’s most prominent private technology companies.

Analysis

This is less an equity-event than a liquidity-repricing event for the entire private-growth complex. A marquee listing at a headline-grabbing valuation tends to pull forward demand from crossover funds, index trackers, and retail options flow, which can temporarily bid up the entire “pre-IPO optionality” basket: late-stage venture, secondary platforms, and market infrastructure names with issuance sensitivity. The key second-order effect is not just enthusiasm for one asset, but a higher reference point for what investors will pay for profitable growth with scarce supply.

For Nasdaq, the more important impact is symbolic and flow-driven than fundamental in the near term. If the deal catalyzes record-setting volume, it likely reinforces NASDAQ’s franchise in large-cap tech formation and boosts associated ancillary revenue—data, connectivity, index inclusion, and derivatives activity—over the next 1-3 quarters. The tradeable upside is not from the listing itself, but from the probability of a sustained “IPO reopening” that revives a pipeline of delayed offerings and secondary block trades.

The contrarian risk is that an oversized offering at an extreme valuation becomes a clearing event rather than a start signal. If the book is dominated by momentum accounts and the post-listing performance fades, the market may conclude that only a handful of trophy assets can clear, while the broader IPO market remains shut. That would cap follow-on issuance, suppress venture exit optimism, and lead to a quick unwind in the most crowded pre-IPO beneficiaries within days to weeks.

The time horizon matters: the immediate reaction should be measured in days around pricing and first trade; the more durable opportunity is 3-6 months if this unlocks a broader capital-markets cycle. If volatility spikes or the deal is repriced lower, the signal flips from “risk-on reopening” to “top-of-cycle valuation stress,” which is bearish for late-stage private marks and for any secondary market names dependent on a healthy IPO calendar.

Key Decisions for Investors

• Buy NDAQ into the pricing window and hold through first-week trading: thesis is higher options/index/data activity and a revived IPO pipeline; target 5-10% upside over 1-3 months, with a tight stop if the deal is materially downsized or poorly received.
• Pair trade: long NDAQ / short a basket of late-stage private-market proxies or secondary-exposed names over 1-3 months. Expect NDAQ to benefit from actual flow while private-markets sentiment can fade if the listing proves more symbolic than catalytic.
• Take a tactical long in IPO-heavy, high-beta market infrastructure via calls or a small equity position 2-4 weeks before trading begins; risk/reward is attractive if first-day volume and retail participation exceed expectations, but size should be limited because the move is event-driven.
• If the IPO prices above the indicated range and opens weak, fade the broader “IPO reopening” trade by shorting recent pre-IPO enthusiasm names for 2-6 weeks. The downside case is a one-off trophy deal rather than a regime shift.